Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 230 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: N Acetyl Cysteine Clear all

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Rifaximin, N-acetylcysteine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Surgical Recovery, Pain, Postoperative
Interventions: N-acetyl cysteine, Normal Saline; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fibromyalgia
Interventions: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo, Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Retinitis Pigmentosa
Interventions: NAC effervescent tablets; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions: N-acetylcysteine; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts

Conditions: Onychophagia
Interventions: N-Acetylcysteine (NAC), Placebo; Drug · Other
Lead sponsor: Kevin Gray, MD; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions: N-acetylcysteine, Oral acetylcysteine; Drug
Lead sponsor: Center for Veterans Research and Education; Other
Eligibility: 40 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autism Spectrum Disorder
Interventions: N-acetylcysteine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 13 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mild Cognitive Impairment
Interventions: Glycine, N-acetylcysteine (NAC), Alanine; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 55 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cocaine Dependence, Healthy
Interventions: N-acetyl cysteine, [18F]FDG PET scan, 1H MRS, [11C]APP311 PET scan; Drug · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Actinic Keratoses
Interventions: 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Acute Respiratory Distress Syndrome
Interventions: N-acetyl cysteine; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: End Stage Liver Failure
Interventions: N-acetylcysteine; Drug
Lead sponsor: Ibtesam Hilmi; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gulf War Syndrome
Interventions: N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: Nova Southeastern University; Other
Eligibility: 47 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Palo Alto, California • Fort Lauderdale, Florida • Boston, Massachusetts + 4 more

Conditions: Cocaine Dependence
Interventions: N-Acetylcysteine, Matching Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Emmanuelle Waubant, MD PhD; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alcohol Use Disorder
Interventions: N-acetylcysteine, Placebo oral capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years to 25 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cannabis Dependence
Interventions: N-Acetylcysteine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 50 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Lexington, Kentucky + 3 more

Conditions: Alcohol Drinking, Control
Interventions: N-Acetylcysteine, Placebo Oral Capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 15 Years to 19 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions: Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 20 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: N-acetylcysteine (NAC), Placebo, Tryptophan; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Feeding Delays, Neonates and Term Infants
Interventions: taVNS, NAC and taVNS, inactive taVNS, sterile water and inactive taVNS; Device · Combination Product
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 39 Weeks to 54 Weeks
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Autism Spectrum Disorder
Interventions: N-Acetylcysteine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: N-acetyl cysteine then Placebo, Placebo then N-acetyl cysteine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Efficacy and Safety of Rifaximin With NAC in IBS-D

Oxidative Stress and Surgical Recovery

The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia

FIGHT-RP 1 Extension Study

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Use of N-Acetylcysteine (NAC) in Fingernail Biting

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Glutathione in Mild Cognitive Impairment

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum

N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome

N-acetylcysteine in Liver Transplantation

GWICTIC: NAC Mechanistic Study in Gulf War Veterans

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

N-Acetylcysteine for Adolescent Alcohol Use Disorder

Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

BabySTrong II taVNS Feeding Trial

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

Inhaled NAC in Treatment of IPF